AAGH America Great Health (PK)

Crown Marketing (OTCQB: CWNM) is pleased to announce that it has filed a provisional patent application with the United States Patent and Trademark Office for a unique and novel dietary supplement.

After researching the most recent developments and studies in nutritional and dietary formulations, Crown believes it has developed a supplement with benefits and efficacy superior to currently available supplements.

Under the America Invents Act (AIA), the U.S. patent laws were amended in ways that represent the biggest changes in decades to U.S. patent law. The most significant changes of the AIA are effective March 16, 2013 and have forever altered the way U.S. patents will be offensively and defensively used in the supplement industry.

The AIA contains many groundbreaking changes to U.S. patent law that will impact the supplement industry for years to come. We believe these changes provide a unique opportunity for Crown to gain a competitive advantage over others who do not incorporate these new changes into their intellectual property strategies.

About Crown Nutraceuticals:

Crown Nutraceuticals is engaged in the development, manufacturing and marketing of popular nutraceuticals and supplements.

The global nutraceuticals product market is massive -- reaching over $142.1 billion in 2011 and the industry is projected to reach $204.8 billion by 2017, with a projected annual growth rate of 6.3% from 2012 to 2017. Asia Pacific (including Japan) is expected to have the second largest market share after North America by 2017. Crown's objective is to rapidly expand its business in the nutraceuticals and supplement market.

About Crown Marketing:

Crown Marketing's Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory along with precise mathematical formulas for precise and programmable diffusion delivery.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chrono-therapeutic requirements. Cost efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact: Charles Van Der Ross 347-491-0565